Aryltricyclospirodienones; novel steroid mimics as inhibitors of aromatase

Abstract

The aryltricyclospirodienones 16a, 16b, 16c and 18 have been designed as potential inhibitors of aromatase and are synthesised from 6-methoxytetralone; † compounds 16a and 18 have proved effective inhibitors with activities of the same order as aminoglutethimide.

References

1. Cytochrome P-450; Structure, Mechanism and Biochemistry, ed. P. R. Ortiz de Montellano, Plenum Press, 1986, pp. 217–271; M. Akhtar, D. E. Stevenson and J. N. Wright, J. Chem. Soc., Perkin Trans. 1, 1988, 2043; J. Y. Kellis and L. E. Vickery, J. Biol. Chem., 1987, 262, 4413, 8840; M. Ahkhtar and J. N. Wright, Nat. Prod. Rep., 1991, 527; E. R. Simpson, M. S. Mahendroo, G. D. Means, M. W. Kilgore, M. M. Hinshelwood, S. Graham-Lorence, B. Amarneh, Y. Ito, C. R. Fisher, M. D. Michael, C. R. Mendelson and S. E. Bulun, Endocr. Rev., 1994, 15, 342.
2. (a) J. O. Johnston and B. W. Metcalf, Novel Approaches to Cancer Chemotherapy, ed. P. S. Sunkara, Academic Press, 1984, p. 307; A. Manni and R. J. Santen, Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion, Bailliere-Tindall, 1987, p. 255; D. F. Covey, Sterol Biosynthesis Inhibitors: Pharmaceutical and Agrochemical Aspects, ed. D. Berg and M. Plempel, Ellis Horwood, 1988, p. 534; M. H. Brodie, Design of Enzyme Inhibitors as Drugs, ed. M. Sander and H. J. Smith, Oxford University Press, 1989, p. 503; (b) Inter alia P. K. Siiteri and E. A. Thompson, J. Steroid. Biochem., 1975, 6, 317; R. W. Bruggemeier, E. E. Floyd and R. E. Councell, J. Med. Chem., 1978, 21, 1007; D. F. Covey, W. F. Hood and V. D. Parikh, J. Biol. Chem., 1981, 256, 1076; B. W. Metcalf, C. L. Wright, J. P. Burkhart and J. O. Johnston, J. Am. Chem. Soc., 1981, 103, 3221; P. A. Marcotte and C. H. Robinson, Biochemistry, 1982, 21, 2773; P. R. Ortiz de Montellano, K. L. Kunze, H. S. Beilan and C. Wheeler, Biochemistry, 1982, 21, 1331; M. G. B. Drew, J. Mann and B. Pietrzak, J. Chem. Soc., Chem. Commun., 1985, 1191; J. N. Wright, M. R. Calder and M. Akhtar, J. Chem. Soc., Chem. Commun., 1985, 1733; L. Tan and A. Petit, Biochem. Biophys. Res. Commun., 1985, 128, 613; M. J. Shih, M. H. Carrell, H. L. Carrell, C. L. Wright, J. O. Johnston and C. H. Robinson, J. Chem. Soc., Chem. Commun., 1987, 213; W. E. Childers and C. H. Robinson, J. Chem. Soc., Chem. Commun., 1987, 320; J. T. Kellis, Jr, W. E. Childers, C. H. Robinson and L. E. Vickery, J. Biol. Chem., 1987, 262, 4421; M. Akhtar, J. N. Wright, P. T. van Leersum and S. G. Chamberlin, J. Chem. Soc., Perkin Trans. 1, 1989, 1647; P. A. Cole and C. H. Robinson, J. Med. Chem., 1990, 33, 2933; J. Am. Chem. Soc., 1991, 113, 8130; R. W. Bruggemeier, Breast Cancer Res. Treat., 1994, 30, 31; H. V. Bossche, H. Moereels and L. M. H. Koymans, Breast Cancer Res. Treat., 1994, 30, 43; J. Geelen, H. J. J. Loozen, G. H. Deckers, R. Deleeuw, H. J. Kloosterboer and S. W. J. Lamberts, J. Steroid Biochem. Mol. Biol., 1993, 44, 681; W. Wouters, E. Snoeck and R. Decoster, Breast Cancer Res. Treat., 1994, 30, 89; P. V. Plourde, M. Dyroff and M. Dukes, Breast Cancer Res. Treat., 1994, 30, 103; A. Lipton, L. M. Demers, H. A. Harvey, K. B. Kambic, H. Grossberg, C. Brady, H. Adlercruetz, P. F. Trunet, R. J. Santen, P. V. Plourde, M. Dyroff and M. Dukes, Cancer, 1995, 75, 2132; N. Oohata, Y. Hori, Y. Yamagishi, T. Fujita, S. Takase, M. Yamashita, H. Terano and M. Okuhara, J. Antibiot., 1995, 48, 757; M. Lourdusamy, F. Labrie and S. M. Singh, Synth. Commun., 1995, 25, 3655; H. I. Holland, S. Kumaresan and G. Lakshmaiah, Can. J. Chem., 1995, 73, 2185; E. J. T. Dasilva, M. L. S. E. Melo and A. S. C. Neves, J. Chem. Soc., Perkin Trans. 1, 1996, 1649; V. C. O. Njar, J. Duerkop and R. W. Hartmann, Steroids, 1996, 61, 138.
3. C. Geynet, C. Millet, H. Truong and E. E. Baulieu, Gynaecol. Invest., 1972, 3, 2; V. C. Jordan and B. Gosden, Mol. Cell. Endrocrinol., 1982, 27, 291.
4. We acknowledge valuable discussions with, and personal communications from, Dr F. T. Boyle, Zeneca Pharmaceuticals, Alderly Park, Macclesfield, UK.
5. D. F. Covey and W. F. Hood, Cancer Res., Suppl., 1982, 42, 3327; G. A. Flynn, J. O. Johnston, C. L. Wright and B. W. Metcalf, Biochem. Biophys. Res. Commun., 1981, 103, 913.
6. Energy minimisations were estimated using MacroModel, version 4.0, with MM2 force field parameters, and employing ‘Monte Carlo’ global searches; we thank Dr M. Luszniak for these calculations.
7. O. Hares, D. Hobbs-Mallyon and D. A. Whiting, J. Chem. Soc., Perkin Trans. 1, 1993, 1481.
8. N. Campbell and D. Kidd, J. Chem. Soc., 1954, 2154.
9. F. M. Dean and K. B. Hindley, Tetrahedron Lett., 1972, 15, 1445.
10. A. S. Hussey and R. R. Herr, J. Org. Chem., 1959, 24, 843.
11. J. K. Stille and R. A. Newsom, J. Org. Chem., 1961, 26, 1375.
12. A generous gift of this material from Zeneca Pharmaceuticals is acknowledged.
13. These assays were conducted by courtesy of Professor P. J. Nicholls, Welsh School of Pharmacy, University of Wales, Cardiff, to whom we express our thanks. Aromatase activity was measured by the release of ³H₂O from (1β-³H)androstendione (0.4 µM) on incubation with placental microsomes (0.15 mg protein ml^–1) at pH 7.4 and 35 °C for 5 min (K_m for aromatase 25 nM). Final inhibitor concentrations 5 × 10^–6M were employed.
14. E. A. Thompson, Jr and P. K. Siiteri, J. Biol. Chem., 1974, 249, 5373; P. E. Graves and H. A. Salhanick, Endocrinology, 1979, 105, 52; C. A. Laughton, R. McKenna, S. Neidle, M. Jarman, R. McCague and M. G. Rowlands, J. Med. Chem., 1990, 33, 2673.
15. T. R. Kasturi and T. Arunachalam, Can. J. Chem., 1968, 46, 3625.
16. D. Lednicer, J. C. Babcock, S. C. Lyster and G. W. Duncan, Chem. Ind., 1963, 408.